Group items tagged

With the upcoming general election on the horizon, Proprietary Association of Greater Britain (PAGB) is leading the charge to integrate self-care into the core of all political party manifestos. The aim is to ease strains on the NHS and forge a sustainable healthcare system for the future. In a significant move, PAGB unveiled a comprehensive general election toolkit on Wednesday, laying out a compelling argument for the prioritisation of self-care among stakeholders. The toolkit underscores the importance of public interest, potential NHS cost savings, and the economic advantages of the over-the-counter (OTC) sector. Aimed at unlocking the full potential of self-care and nurturing an enabling environment for its implementation, PAGB's toolkit advocates for greater integration of pharmacy services into primary care.

Haleon is enhancing its research and development (R&D) capabilities and accelerating its new product innovation pipeline with a $54 million (£43.49 million) investment in its global R&D centre of excellence in Richmond, Virginia, USA. This investment is in addition to the company's annual R&D budget of approximately £300 million. The Richmond site, one of Haleon's three global R&D centres of excellence, alongside facilities in Weybridge, UK, and Suzhou, China, provides the global scale necessary for the company to deliver disruptive and locally relevant brand innovations across over 170 markets worldwide. The upgraded facility will feature new, state-of-the-art laboratories designed to enable development of innovations across ingredients, formulations, flavours, formats and packaging for Haleon's Over-the-Counter (OTC) and Vitamins, Minerals and Supplements (VMS) categories. Franck Riot, Haleon's chief R&D officer, emphasised the critical role of R&D in the company's success, stating, "R&D is the cornerstone of our business and the innovation engine behind our category-leading brands." "Consumers trust our products because they trust our science - so investing in R&D is vital for driving consumer preference for our brands."

Shoulder pain is one of the most common types of pain that impacts your mobility and daily activities. Often associated with heart disease, shoulder pain can also occur due to an injury, trauma, or a medical condition like arthritis. While over-the-counter medications might help relieve the pain, it is crucial to address the cause of the pain becoming frequent. In this guide, we will be sharing particular situations that require a visit to an orthopedic doctor so you can get the appropriate treatment. AFTER AN ACCIDENT Minor injuries and accidents can cause inflammation and pain at the injury site which can be resolved by taking OTC medications and giving the body time to heal. However, in severe injuries, the joint may get swollen in an instant, cause extreme pain, or may seem deformed. In situations like these, there is a likelihood of a fracture and the injury then needs to be evaluated by a specialist. Depending on the severity of the accident, either the shoulder will be immobilized or operated on to repair the damage. If you have a broken shoulder, get plenty of rest, eat healthily, and follow your doctor's instructions for a quick recovery.

Community pharmacies, like any business, face financial challenges, and one significant concern is managing cash flow. Your business requires cash flow to pay for stock, suppliers, operational costs, taxes and service bank debts and these need to be matched with cash inflows from NHS remuneration, Over The Counter (OTC) sales and HMRC VAT refunds otherwise you could find yourself in a vicious circle. If cash flow is not monitored, you will find the business juggling to settle its liabilities as they fall due. If suppliers are not paid on time, they will not send vital supplies which in turn results in customers going elsewhere. If staff/locums are not paid on time, your patients will suffer due to lack of staff or even poor service levels from demotivated staff. HMRC can issue debt recovery proceedings against the business if debts remain unpaid. Lenders will be keeping a keen eye on the management accounts to ensure the business remains strong and is able to settle its financial obligations as they fall due. Let's explore how UK community pharmacies can identify potential cash flow problems and implement strategies to navigate these challenges effectively. Dispensed items If you are experiencing a drop in the average number of items you are dispensing over time, then it could mean customers could be going elsewhere. Loss of customers will mean less income for the business, and it is always difficult to get them back especially when they have gone to a local competitor. You need to keep an eye on this indicator and investigate any drop in numbers. Implement alternative strategies as to how you may increase this for example through partnerships with local community centres, GP surgeries, colleges, etc.

Drugmaker Viatris said on Sunday (October 1) it had reached agreements to divest some of its businesses for a total of about £2.9 billion. Viatris said its move to divest some of its businesses is part of its long-term strategy to streamline focus on three core therapeutic areas - ophthalmology, gastroenterology and dermatology. The company has received an offer of about $2.17 billion (£1.78 billion) for almost all of its over-the-counter drug business from France-based Cooper Consumer Health. Viatris will retain rights for erectile dysfunction drug Viagra, nasal spray Dymista and select OTC drugs within certain markets. Separately, the drugmaker said it has agreed to sell its women's healthcare business to Spanish pharmaceutical company Insud Pharma, while its active pharmaceutical ingredients business in India will be sold to Iquest Enterprises. Both divestitures would result in about $1.2 billion (£987 million) in proceeds.

Published 01 May 2014 ACETO has announced that its wholly-owned subsidiary, Rising Pharmaceutical, has closed the acquisition of 100% of the equity interests of PACK Pharmaceuticals, a national marketer and distributor of generic prescription and over-the-counter pharmaceutical products. The total transaction value is approximately $100m.